Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Int J Antimicrob Agents

Laboratory for Antimicrobial Pharmacodynamics, NYS Center of Excellence in Bioinformatics & Life Sciences, Buffalo, NY, USA; School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA. Electronic address:

Published: December 2016

The objective of this study was to determine the comparative pharmacodynamics of four different carbapenems in combination with polymyxin B (PMB) against carbapenem-resistant Acinetobacter baumannii isolates using time-kill experiments at two different inocula. Two A. baumannii strains (03-149-1 and N16870) with carbapenem minimum inhibitory concentrations (MICs) ranging from 8 to 64 mg/L were investigated in 48-h time-kill experiments using starting inocula of 10 CFU/mL and 10 CFU/mL. Concentration arrays of ertapenem, doripenem, meropenem and imipenem at 0.25×, 0.5×, 1×, 1.5× and 2× published maximum serum concentration (C) values (C concentrations of 12, 21, 48 and 60 mg/L, respectively) were investigated in the presence of 1.5 mg/L PMB. Use of carbapenems without PMB resulted in drastic re-growth. All carbapenem combinations were able to achieve a ≥3 log CFU/mL reduction by 4 h against both strains at 10 CFU/mL, whereas maximum reductions against strain 03-149-1 at 10 CFU/mL were 1.0, 3.2, 2.2 and 3.3 log CFU/mL for ertapenem, doripenem, meropenem and imipenem, respectively. None of the combinations were capable of reducing 10 CFU/mL of N16870 by ≥2 log CFU/mL. Ertapenem combinations consistently displayed the least activity, whereas doripenem, meropenem and imipenem combinations had similar activities that were poorly predicted by carbapenem MICs. As doripenem, meropenem, or imipenem displayed similar pharmacodyanmics in combination, the decision of which carbapenem to use in combination with PMB may be based on toxicodynamic profiles if drastic discordance in MICs is not present.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237376PMC
http://dx.doi.org/10.1016/j.ijantimicag.2016.07.024DOI Listing

Publication Analysis

Top Keywords

doripenem meropenem
16
meropenem imipenem
16
log cfu/ml
12
comparative pharmacodynamics
8
pharmacodynamics carbapenems
8
carbapenems combination
8
combination polymyxin
8
carbapenem-resistant acinetobacter
8
acinetobacter baumannii
8
time-kill experiments
8

Similar Publications

Carriage of antimicrobial resistance genes in Escherichia coli of bovine origin.

Pol J Vet Sci

December 2024

Department of Animal Nutrition and Husbandry, University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, Košice, 04181, Slovakia.

The present study aimed to search for the presence of the plasmid-mediated antimicrobial resistance genes in 106 Escherichia coli (E. coli) isolates from a total of 240 fresh fecal samples collected from 12 private cattle farms in Bingol province of East Turkey from November 2021 to January 2022. In those colistin-resistant E.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the rising prevalence of carbapenem-resistant Acinetobacter baumannii (CRAB) in healthcare settings, identifying significant global health concerns due to limited treatment options.
  • It includes data from 795 studies across 80 countries and highlights substantial increases in antibiotic resistance rates from 1995 to 2023, particularly between 2020 and 2023.
  • The findings stress the urgent need for targeted interventions and improved collaboration to address this escalating public health issue.
View Article and Find Full Text PDF

Genomic analysis of blaNDM-1-carrying-Pseudomonas aeruginosa ST2407 in the chromosome from Brazil.

Infect Genet Evol

December 2024

Laboratório de Bacteriologia Aplicada à Saúde Única e Resistência Antimicrobiana (LABSUR), Instituto Oswaldo Cruz - FIOCRUZ, Rio de Janeiro, Brazil. Electronic address:

Pseudomonas aeruginosa, an opportunistic pathogen often found in Healthcare-associated infections (HAI), has shown increased resistance to carbapenems (imipenem, meropenem, doripenem), the primary treatment options. We've seen a rise in carbapenemase-producing P. aeruginosa in Brazil, including NDM-producers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!